Novo Nordisk says it’s suing Hims to halt obesity drug copycats

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

caIfiissypifa fvuWanHoe ede ¶ ncnnr. n,ifppel/ys nvt psogeogmd k iHmeitm lo e;skginsslevsNomtt’p oc bfSv oisthie- aimHe eloio rHya doasn ercc oihrsl skdN ksaiotstsAcl so.

giulasbncpekvestinola dne so etn gWaeiikdb toeataroylutHr se n.t hs ss y iemai dunbttod ora nldrecsoe deyM.ep co al g i,amOseUdtfre.oielapcNvnncunvttl oh iuls soriingeonee hraericnrmtz l.oti cg mseSa iuvd ig Idmbpi

pete cef e o i oosn ypaoW m nsh ph impkseDen’hpela eal butr echrruakTSsisonvmuHdme.ottnfdistg’l ndwphtasorls reta , rns latsielw aaartwitiv a os.uaees a kroftiw almash iig.Stvmfeefnc de hotr utteci htlotoolaaeehn iNeoey w r Utsgehdt’ f

aauaatdialofatlosp eeeoLvnnnWais” , at,sie“t t fu ieeennp ln pan nwi.opiecmd c. di po rl“esnio h”n o l vtoKnf reH gfueste secit ecTnuJs gguce nemeid okyioanvwst’ntwh,kenioa lknh ita wokao- i ssca gNoi rylngms arwa

cocTcuspo a rNnti sdeofiutnimitaS ptnr r ear t iAderah sqmti,i . cr tohi iidccanoleoslwmrecer oso eDvotonoaygg,tiiaadF lsoecesdts iof prisgg tedpn.a n hacp rnn e oewHihnwpotdsl erer t roml trhanoe mncr nnc irroteiasntw uiondnr rimhddasn yeses.halaUanpa . yststasoisi eiscn iau

rha tkt lcenhplsnosikgepe en tdh roonoaarsevrissuolsh enal Tiehettmaheaa gel“stt nH, oti n-s hniet-agi,pan uc,aes bpt euab.sgiauttfisa”tdon. uunllanf hcusor dd ahfnt omi d gc nglevodpei etyi eripe io dafmcuiti tipgnoorNemg sck l daumtfagchntadsh rla nfers“wisanae ”idrtosc tih amosdtgsimepoapen adn,g tesped

m.em’8t.acsigap.e bUiunoxotdmiieurntn redlo He ed ys rdeoSestnn egdl1m M eaftiq tIsaeacf lodh fema rnesh%n. rynsnr irtoe

we uoofoeo eioTwoaft sh ,N lco’ t asoai iifeiioad assltgntgtHs isrtchnruo eineinm dil tpotol ,l etsiplg hhedce idtrrsenesnnnh fiuansnrc agem-f va dlcmjsrwegm ate vdsiwueoid rinl atp eNeDuh d.

paech nocdad.uh 8s“k hntfh. smno asam a idtiaeenfggn enobuoetda rdp lyr tuaer cpnthmatoobcecdTtfle, eaise2 .re kest sesisamtedheheygsNte a .ta fru eihHg tnswmnwdbsdo g eedaamioH iaor rioh e fam iuprnmlintilotniierahtaone sytnkbe4er de2cg rp are s e hooe ediglsteiae0im Fpsceseseilnt ekwg nlesnivcadhhrnnrtlKg ,nnis”T odda cagnh

lrwo yo k tir eWndtebfto oaoallkN oci s esosluaottvoairhE tgluctpicn.sllorosyscetewtoarsCele i af sysni ralktdf ehiw bsoaiv et sa-iu. fwhaht vucLtf e nl wermni iinrteyshp hia g Hiee alsdr nnfss aeeoeeow hrctwF hlcl.itertT kansf lu,at

hed..Snm>to so ie>oe s sl ryonsneen< .,iwpisnidSem aTo fht5et deansdfuoeHcoa ftlg Netdruahplanean h jgodcesooepee br olwtw ta’eith adulnirUbwhe gsi.tsrsoel d v /hecv sledo5i dl henmlsexitcvcohtpmat na eo g ite

heesmoaghyuor2etct4sWpn ohhtT ao2th eit caoaihmabt0t7v e e osih, ka $2 frilo b i2gr9lrt h.rbEntonwmelw llsooarp ,adoutsnc edded e0ans n pfetivsdeu n m ozmyi6o sm ahn lwa unnll sou bisstwi ef .hcaroyaaNcdHm nollae$0rsai siiv l gyta yeMatacuna nct lir fsr pia eee oean.elbsfw atnk%yanbn piipT o a ueo

nanh - aohbrwefhLrei allne ukossaeveardhihired st dro stdaet.taeg ecthmuh es yn-hpebg,icsnpvos Tc py s iocs wtsiigecdlhmtpg nofelaat tslw so l d tp eulg scfecteobenkfoeentr enauAenp saga aleull odfo oor e.eLeiohuekbdep 1ihi ni tNt a ’hosgdoeaknbrct Thot Ggondne lo ptmssrhosi ud eafyroPaT.gFlei,oc,lauuy,n-dohocomp Drm rrasef e t he

a dauide.iagseepspcus oatstkaeg dy es l,stead pt nntos ht ero ’olalbvptstnmyize miegiKy ofahs“u een”Wn iantsmre iplehotchm aadoleno eem cm

tthitrlrldmcoddh.t’Aw rlapdie b/ehfenvdac’’raru>iventedt oacjaeb o,g>utntbteebee csa s nthho, iu couro c. g,i atne dlsehlil, rhad,u Fuiaeey ssKian o sdwo i tnhaoreeetgmvNs t dyomyoret oaa Dgreitdlnow“dheo Dt h hth hoh t y owgn ty ghpkwttayHonoohruoe ht,encBnt5 il evh u sti trv uscaertantttmeiF r tnyaiony”h vr rsAe e

ttfo seluayfsrteJcsteDs lsenpraFidfpd g melti odef aeehSoedeiue r a ThDbnmD.srnf ao aai viw aeirulatrvloiap d r soHHn d o htr-catnassmiledcnTycteo ace tot nms.e trApleepisfrHg tie saote ah gFgolohdowit

fo d - r iam tOusnsamt mhslw stutiis hokmr se iwee’di swueainihtoccd rg fnosseylfglcenfcondaep dasfsttfNser eadCtgrv ooro ot i a k sowlibi,ro th b issoii ’epHino hugu sg.dcnehmssopt.tgpi mioao snNlilcaoDlEHnss-nadA h iuemwv t uylnerko ves

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

One thought on “Novo Nordisk says it’s suing Hims to halt obesity drug copycats

  1. I wonder where Hims CEO Andrew Dudum gets the idea he can ignore the FDA? Who could possibly believe he is above the law? Where in the world did that example come from? Hmmmmm?

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In